Home Alzheimer’s Disease JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma

JNJ-4528 Continues to Show Durable Responses in Relapsed/Refractory Multiple Myeloma

JNJ-4528, a chimeric antigen receptor (CAR) T-cell therapy, continued to demonstrate deep and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma, according to updated findings from the phase 1b/2 CARTITUDE-1 (NCT03548207) trial presented during 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.1

Lead author Jesus G. Berdeja, MD, reported that the overall response rate (ORR) was 100%, with a stringent complete response (sCR) rate of 86% (25 out of 29 patients). Further, the progression-free survival (PFS) rate was 86% (95% CI, 67%-95%) at 9 months. Results were 

The objective of the phase 1b portion of CARTITUDE-1 was to determine the safety of the B-cell maturation antigen (BCMA) and confirm the dose for future research. Phase 2 is investigating the efficacy in terms of ORR, defined by the International Myeloma…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments